Alkermes plc. (ALKS) Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - Specialty & Generic
Alkermes plc NASDAQ:ALKS Healthcare · Drug Manufacturers - Specialty & Generic
Mkt Cap $7.61B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)
Alkermes initiated a Phase 2 proof-of-concept study of ALKS 7290, an oral orexin 2 receptor agonist, as an adjunctive therapy to antidepressants in adults with major depressive disorder.
The randomized, double-blind, placebo-controlled trial will enroll approximately 180 participants for six weeks of treatment, with safety as the primary objective and MADRS/CGI-S symptom improvement as secondary endpoints.
The launch extends the orexin agonist franchise beyond ADHD and narcolepsy into depression, though data are likely years away.
• 2d ago AI analysis › Press Release
Alkermes to Report Third Quarter Financial Results on November 3, 2026
Alkermes plc will host its third quarter 2026 earnings conference call and webcast at 8:00 a.m. ET on Tuesday, November 3, 2026.
The release contains no financial results or guidance — it is solely a scheduling notice with dial-in and webcast details.
Slides and a replay will be available via the investor relations section of the company's website.
• 12d ago AI analysis › Press Release ⚠ 1
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research
Alkermes will present two oral presentations and six posters on alixorexton and LUMRYZ at the ESRS Sleep Europe 2026 congress (Oct. 20-23, Maastricht).
The orals cover Vibrance-1 Phase 2 data on alixorexton in narcolepsy type 1, nine-month long-term extension results, and detailed Phase 3 REVITALYZ results of LUMRYZ in idiopathic hypersomnia, whose positive topline was previously announced.
Alixorexton holds FDA Breakthrough Therapy designation for NT1 and Orphan Drug status, and is in Phase 3 Brilliance trials plus Phase 2 Vibrance-3 in IH.
No new efficacy figures were disclosed; the release is a calendar announcement reinforcing Alkermes' sleep-medicine franchise, which expanded with the Avadel acquisition.
• 19d ago AI analysis › Press Release ⚠ 3
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Alkermes reported positive Phase 1b proof-of-concept results for ALKS 7290, an investigational oral orexin 2 receptor agonist, in 50 adults with ADHD — the first clinical evidence of an orexin agonist delivering clinically meaningful improvements in ADHD symptoms.
At day 14, median AISRS total scores fell 14.0 points on the 20 mg dose and 19.0 points on the 50 mg dose, with CGI-S reductions of 1.0 and 2.0 respectively; the drug was generally well tolerated, with no serious treatment-emergent adverse events and no discontinuations among participants receiving ALKS 7290.
The study was exploratory and not powered for statistical significance; a Phase 2 study enrolling approximately 312 adults is already enrolling, with data expected in 2027.
• 1mo ago AI analysis › Press Release
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors
Alkermes plc (Nasdaq: ALKS) announced the appointment of Anne C. Whitaker as a new independent director on its Board.
Whitaker is a veteran biopharmaceutical executive who most recently served as CEO of Aerami Therapeutics and previously led Novoclem Therapeutics and Synta Pharmaceuticals, with senior commercial roles at Sanofi and GlaxoSmithKline; she currently sits on the boards of Basilea Pharmaceutica and ICON plc.
CEO Blair Jackson said Whitaker joins at a defining time as Alkermes builds on strong commercial performance and advances a differentiated neuroscience pipeline.
This is a routine governance update with no financial terms attached; the addition of deep commercial and operational expertise is a modest positive for board composition but does not change the investment thesis.
• 1mo ago AI analysis › Press Release
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program
Alkermes opened applications for the 9th annual Alkermes Pathways Research Awards, a competitive grant program offering up to $100,000 per project to early-career neuroscience researchers at U.S. institutions.
The 2026 cycle expands areas of interest to narcolepsy type 1 and 2 and idiopathic hypersomnia alongside schizophrenia and bipolar I disorder, with letters of intent accepted from Sept. 11 through Oct. 16, 2026.
Since launching in 2018, the program has provided roughly $2.9 million in funding to 29 researchers. The hypersomnolence focus mirrors Alkermes' late-stage clinical programs in narcolepsy and idiopathic hypersomnia, though no new pipeline or financial data was disclosed.
• 1mo ago AI analysis › Press Release ⚠ 1
Tortugas Neuroscience Announces Appointment of Jim Frates to Board of Directors
Tortugas Neuroscience, a private clinical-stage CNS biotech launched in April 2026, appointed Jim Frates to its Board of Directors and as Chair of its Audit Committee.
Frates has served as CFO of Amylyx Pharmaceuticals (Nasdaq: AMLX) since 2021 and previously spent more than two decades as CFO of Alkermes plc (Nasdaq: ALKS), during which Alkermes grew past $1 billion in revenue and 2,000 employees.
For filer ALKS the news is tangential: Frates left Alkermes years ago, and the appointment at an unrelated private company has no bearing on Alkermes' operations, financials, or governance.
• 1mo ago AI analysis › Press Release ● Major
The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
The Lancet Neurology published positive Phase 2 data from the Vibrance-1 study of Alixorexton for narcolepsy type 1, demonstrating statistically significant improvements in wakefulness and sleepiness.
The study of 92 adults showed that all tested doses (4 mg, 6 mg, 8 mg) achieved normative ranges on key sleep scales, with the treatment generally well tolerated and no serious adverse events reported.
Based on these results, Alkermes has initiated the global Phase 3 Brilliance Studies, supported by the drug's Breakthrough Therapy and Orphan Drug designations.
• 2mo ago AI analysis › Press Release
Alkermes plc Reports Second Quarter 2026 Financial Results
Alkermes plc reported financial results for the second quarter of 2026, covering the period ended June 30, 2026.
The company scheduled a conference call and webcast for today to discuss the quarterly results and provide an update on business expectations.
Investors are directed to the company's investor relations website for the detailed earnings release and presentation materials.
• 3mo ago AI analysis › Press Release
Alkermes to Report Second Quarter Financial Results on July 28, 2026
Alkermes plc announced it will report its second quarter financial results on July 28, 2026, via a conference call and webcast.
The event is scheduled for 8:00 a.m. ET, with live access available through the company’s website or via phone for U.S. and international listeners.
A replay of the webcast will be accessible approximately two hours after the conclusion of the call.
• 3mo ago AI analysis › Press Release ● Major
Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis
Alkermes reported positive interim results from a long-term extension study of Alixorexton, showing sustained improvements in wakefulness and sleepiness for adults with narcolepsy type 1 and type 2 over approximately nine months.
Patient-reported outcomes for cognition and fatigue also showed sustained improvement, while the drug was generally well-tolerated with no serious adverse events reported.
The data supports the ongoing Phase 3 Brilliance studies, with management planning to present detailed results at a future medical meeting.
• 3mo ago AI analysis › Press Release ● Major
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
Alkermes announced positive detailed results from the Phase 2 Vibrance-2 study of alixorexton in adults with narcolepsy type 2.
The study met its dual primary endpoints, demonstrating statistically significant and clinically meaningful improvements in wakefulness and excessive daytime sleepiness compared to placebo on the MWT and ESS scales.
Safety was favorable with no serious treatment-emergent adverse events reported, and the company has initiated a global Phase 3 program based on these findings.
• 4mo ago AI analysis › Press Release
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe
Alkermes announced that its investigational orexin 2 receptor agonist, alixorexton, has received orphan drug designations from both the FDA and the European Commission.
The FDA granted designation for the treatment of idiopathic hypersomnia (IH), while the European Commission granted it for narcolepsy. These designations unlock significant development incentives, including tax credits, fee waivers, and potential market exclusivity periods of seven years in the U.S. and up to ten years in Europe.
Alixorexton is currently in Phase 3 trials for narcolepsy types 1 and 2 (the Brilliance Studies) and Phase 2 for IH (Vibrance-3). The company notes that IH affects an estimated 40,000 people in the U.S., highlighting the rare-disease focus of this regulatory milestone.
• 4mo ago AI analysis › Press Release
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
Alkermes will present 26 abstracts at SLEEP 2026, headlined by an oral presentation of detailed positive results from the Vibrance-2 Phase 2 study of alixorexton in narcolepsy type 2.
The company will also share baseline characteristics from the Phase 3 REVITALYZ study of LUMRYZ in idiopathic hypersomnia, where positive topline results were recently announced.
These presentations underscore Alkermes' expanded sleep medicine portfolio following its acquisition of Avadel Pharmaceuticals and the progression of its novel orexin agonist program.
• 4mo ago AI analysis › Press Release
Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Alkermes management will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference.
The session is scheduled for Wednesday, June 10, 2026, at 10:00 a.m. ET.
A live webcast will be available on the company's investor relations website and archived for 14 days.
• 4mo ago AI analysis › Press Release
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
Alkermes will present 11 posters at the American Society of Clinical Psychopharmacology Annual Meeting in Miami, May 26-29, 2026.
The presentations cover real-world data for commercial assets LYBALVI and ARISTADA, as well as clinical data for investigational orexin agonists including alixorexton.
Key highlights include Phase 2 Vibrance-1 results for alixorexton in narcolepsy type 1 and real-world adherence analyses for LYBALVI in schizophrenia.
• 5mo ago AI analysis › Press Release
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences
Alkermes announced the presentation of accepted research at five major spring scientific conferences, including the American Psychiatric Association (APA) and ISPOR.
The presentations focus on real-world evidence and clinical data for its psychiatry portfolio, specifically LYBALVI and ARISTADA, highlighting treatment adherence, persistence, and relapse rates in schizophrenia and bipolar I disorder.
The company also showcased data from its sleep medicine research, including the ASPIRE study on narcolepsy and idiopathic hypersomnia, reinforcing its neuroscience focus.
• 5mo ago AI analysis › Press Release ● Major
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
businesswire.com • 5mo ago Press Release
Alkermes plc Reports First Quarter 2026 Financial Results
Alkermes plc reported financial results for the first quarter of 2026 and provided expectations for the full year. The detailed earnings press release and presentation are available on the company's investor relations website.
The company will host a conference call and webcast at 8:00 a.m. ET today to discuss the results and provide a corporate update.
Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products addressing alcohol dependence, opioid dependence, schizophrenia, and narcolepsy.
• 5mo ago AI analysis › Press Release
Alkermes to Report First Quarter Financial Results on May 5, 2026
Alkermes plc announced that it will report its first quarter financial results on May 5, 2026, via a conference call and webcast.
The event is scheduled to begin at 8:00 a.m. ET, with access available through the Investors section of the company's website or via telephone.
A replay of the webcast will be available approximately two hours after the conclusion of the call.
• 6mo ago AI analysis › Press Release ● Major
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
businesswire.com • 6mo ago Press Release
Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry
businesswire.com • 6mo ago Press Release ● Major
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
businesswire.com • 7mo ago 
